---
title: "Columbia Financial deregisters common stock under Exchange Act reporting rules"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293322209.md"
description: "Columbia Financial has filed to deregister its common stock under Exchange Act reporting rules. The company reported that it has no remaining classes of securities subject to ongoing periodic reporting and listed no holders of record as of July 20, 2026."
datetime: "2026-07-21T10:00:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293322209.md)
  - [en](https://longbridge.com/en/news/293322209.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293322209.md)
generator: "portal-rs"
---

# Columbia Financial deregisters common stock under Exchange Act reporting rules

-   Columbia Financial filed to deregister its common stock, par value $0.01 per share. \* It reported no remaining classes of securities subject to ongoing periodic reporting. \* The filing listed no holders of record as of July 20, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Columbia Financial Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-309130), on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CLBK.US](https://longbridge.com/en/quote/CLBK.US.md)

## Related News & Research

- [Columbia Financial amends 8-K to disclose board committee assignments for new directors](https://longbridge.com/en/news/294117089.md)
- [Singapore Index Fund amends trust deed to add electronic transfers, phase out cheques from Oct. 1, 2026](https://longbridge.com/en/news/298710637.md)
- [Damartex reports FY2025-26 annual results release available](https://longbridge.com/en/news/298344100.md)
- [BioLineRx outlines Phase 1/2a GLIX1 trial in recurrent high-grade glioma at EANO 2026](https://longbridge.com/en/news/298582374.md)
- [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**